ICCC | Ticker Profile - Titan Protect

ICCC

ImmuCell Corporation

Healthcare · Biotechnology · NCM

$9.61

Data: 2026-05-15

✓ ETHICAL PASS

MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$79M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-79.55

Based on estimated future earnings — lower means cheaper

Rev Growth

-1.6%

Year-over-year revenue change

Profit Margin

-3.8%

How much profit the company keeps from each dollar of revenue

ROE

-3.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

https://immucell.com

Country: United States Employees: 73 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

17.7% PASS

Debt must be below 33% of total assets

Cash Ratio

5.1% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.046

Excellent risk-adjusted returns

Kelly Fraction

0.0592

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.380

Returns exceed worst-case losses — strong risk profile

Annual Return

55.2%

Historical annualised return based on price data

Max Drawdown

-40.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.51

Less volatile than the market — more defensive

52W High

$9.08

-6% below the year high

52W Low

$4.52

113% above the year low

Avg Volume

19,353

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

0.2%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.12

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.49

Conservative use of debt — low financial risk

Current Ratio

4.26

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.82

Like current ratio but excludes inventory — stricter test

Gross Margin

41.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

9.7%

Profit from core operations before interest and tax

Free Cash Flow

$998,360

Positive — the business generates more cash than it spends

Revenue (TTM)

$28M

Total revenue over the last 12 months

Net Income

$-1,040,027

Loss-making — spending exceeds revenue after all costs

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Shares	Value
2026-03-20	BRIGHAM MICHAEL F	Director	25,000	$146,000
2025-12-04	TE BOEKHORST PAUL FRANCIS OLIVIER	Chief Executive Officer	9,738	$49,581
2025-12-03	TE BOEKHORST PAUL FRANCIS OLIVIER	Chief Executive Officer	9,785	$48,588
2025-11-25	TOMSCHE DAVID SCOTT	Director	3,266	$15,554
2025-06-12	GATHAGAN BRYAN K	Director	1,000	$6,320
2025-06-11	BASSE GLORIA F	Director	3,530	$16,979

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go